Publication of data from WIL-31 study marks a milestone in improving long-term care for patients with severe von Willebrand disease

Octapharma AG Austria Belgium France Germany Italy Netherlands Spain Switzerland United Kingdom

WIL-31 is the largest prospective prophylaxis study in VWDWIL-31 is the only study in VWD with a prospective on-demand run-in study as an intra-individual comparatorwilate® prophylaxis is highly effective at reducing bleeding rates in children and adults with all types of VWD vs prior on-demand treatmentView original content:https://www.prnewswire.co.uk/news-releases/publication-of-data-from-wil-31-study-marks-a-milestone-in-improving-long-term-care-for-patients-with-severe-von-willebrand-disease-vwd-302040575.html